Mod­er­na gets Au­to­lus tar­get­ing tech via li­cens­ing deal; Atai re­ports PhI da­ta for kratom-based ther­a­py

A year af­ter Au­to­lus Ther­a­peu­tics got it­self a part­ner in Mod­er­na via a li­cens­ing deal, Mod­er­na is ex­er­cis­ing its op­tion to ac­quire the biotech’s pro­pri­etary binders.

The Lon­don-based Au­to­lus re­vealed the op­tion Wednes­day morn­ing, say­ing that the mR­NA gi­ant has ex­er­cised its op­tion to in-li­cense for an undis­closed I/O tar­get. The orig­i­nal agree­ment be­tween the two com­pa­nies was reached back in Au­gust 2021, which gave Mod­er­na the op­tion to li­cense Au­to­lus’ tech for up to four im­mune-on­col­o­gy tar­gets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER